Search

Your search keyword '"Bröckelmann, Paul J."' showing total 21 results
Start Over Author "Bröckelmann, Paul J." Publisher wiley
21 results on '"Bröckelmann, Paul J."'

2. Low B‐cell content is associated with a CD73 ‐low tumour microenvironment and unfavourable prognosis in classic Hodgkin lymphoma

Author

Grund, Johanna, primary, Iben, Katharina, additional, Reinke, Sarah, additional, Bühnen, Ina, additional, Plütschow, Annette, additional, Müller‐Meinhard, Berit, additional, Garcia Marquez, Maria A., additional, Schlößer, Hans A., additional, von Tresckow, Bastian, additional, Kellermeier, Fabian, additional, Borchmann, Peter, additional, Engert, Andreas, additional, Bröckelmann, Paul J., additional, and Klapper, Wolfram, additional

Published
2023
Full Text
View/download PDF

4. JAK inhibition with ruxolitinib in relapsed or refractory classical Hodgkin lymphoma: Final results of a phase II, open label, multicentre clinical trial (JeRiCHO)

Author

Gillessen, Sarah, primary, Pluetschow, Annette, additional, Vucinic, Vladan, additional, Ostermann, Helmut, additional, Kobe, Carsten, additional, Bröckelmann, Paul J., additional, Böll, Boris, additional, Eichenauer, Dennis A., additional, Heger, Jan‐Michel, additional, Borchmann, Sven, additional, Fuchs, Michael, additional, Borchmann, Peter, additional, Engert, Andreas, additional, and von Tresckow, Bastian, additional

Published
2022
Full Text
View/download PDF

5. Immunity after COVID-19 vaccination in people with higher risk of compromised immune status: a scoping review

Author

Kreuzberger, Nina, additional, Hirsch, Caroline, additional, Andreas, Marike, additional, Böhm, Lena, additional, Bröckelmann, Paul J, additional, Di Cristanziano, Veronica, additional, Golinski, Martin, additional, Hausinger, Renate Ilona, additional, Mellinghoff, Sibylle, additional, Lange, Berit, additional, Lischetzki, Tina, additional, Kappler, Verena, additional, Mikolajewska, Agata, additional, Monsef, Ina, additional, Park, Yun Soo, additional, Piechotta, Vanessa, additional, Schmaderer, Christoph, additional, Stegemann, Miriam, additional, Vanshylla, Kanika, additional, Weber, Florencia, additional, Weibel, Stephanie, additional, Stephani, Caspar, additional, and Skoetz, Nicole, additional

Published
2022
Full Text
View/download PDF

6. Outcomes of anti‐programmed death 1 treatment for relapsed/refractory Hodgkin lymphoma: A German Hodgkin Study Group multicentre real‐world analysis

Author

Momotow, Jesko, primary, Bühnen, Ina, additional, Trautmann‐Grill, Karolin, additional, Kobbe, Guido, additional, Hahn, Dennis, additional, Schroers, Roland, additional, Heinrich, Bernhard, additional, Gaska, Tobias, additional, Forstbauer, Helmut, additional, Schmidt, Burkhard, additional, Boger, Regina, additional, Hüttmann, Andreas, additional, Heil, Gerhard, additional, Kraemer, Doris M., additional, Krüger, William, additional, Zeremski, Vanja, additional, Grobe, Norbert, additional, Jentsch‐Ullrich, Kathleen, additional, Griesinger, Frank, additional, Fuchs, Michael, additional, von Tresckow, Bastian, additional, Borchmann, Peter, additional, Engert, Andreas, additional, and Bröckelmann, Paul J., additional

Published
2022
Full Text
View/download PDF

8. Impact of timing and precision of histopathological diagnosis on outcomes of patients with Burkitt Lymphoma and High‐Grade B‐Cell Lymphoma

Author

Graef, Claus Moritz, primary, Gödel, Philipp, additional, Falderbaum, Philipp, additional, Balke‐Want, Hyatt, additional, Simon, Florian, additional, Sieg, Noëlle, additional, Naendrup, Jan‐Hendrik, additional, Neumann, Marie Anne‐Catherine, additional, Gillessen, Sarah, additional, Bröckelmann, Paul J., additional, Eichenauer, Dennis A., additional, Borchmann, Peter, additional, von Tresckow, Bastian, additional, and Heger, Jan‐Michel, additional

Published
2022
Full Text
View/download PDF

9. Reinduction therapy with everolimus in combination with dexamethasone, high‐dose cytarabin and cisplatinum in patients with relapsed or refractory classical Hodgkin lymphoma: an experimental phase I/II multicentre trial of the German Hodgkin Study Group (GHSG HD‐R3i)

Author

Gillessen, Sarah, primary, Hüttmann, Andreas, additional, Vucinic, Vladan, additional, Müller, Horst, additional, Plütschow, Annette, additional, Viardot, Andreas, additional, Topp, Max S., additional, Kobe, Carsten, additional, Böll, Boris, additional, Eichenauer, Dennis A., additional, Sasse, Stephanie, additional, Haverkamp, Heinz, additional, Schmitz, Christine, additional, Borchmann, Sven, additional, Bröckelmann, Paul J., additional, Heger, Jan‐Michel, additional, Fuchs, Michael, additional, Engert, Andreas, additional, Borchmann, Peter, additional, and Tresckow, Bastian, additional

Published
2021
Full Text
View/download PDF

11. 9p24.1 alterations and programmed cell death 1 ligand 1 expression in early stage unfavourable classical Hodgkin lymphoma: an analysis from the German Hodgkin Study Group NIVAHL trial

Author

Gerhard‐Hartmann, Elena, primary, Goergen, Helen, additional, Bröckelmann, Paul J., additional, Mottok, Anja, additional, Steinmüller, Tabea, additional, Grund, Johanna, additional, Zamò, Alberto, additional, Ben‐Neriah, Susana, additional, Sasse, Stephanie, additional, Borchmann, Sven, additional, Fuchs, Michael, additional, Borchmann, Peter, additional, Reinke, Sarah, additional, Engert, Andreas, additional, Veldman, Johanna, additional, Diepstra, Arjan, additional, Klapper, Wolfram, additional, and Rosenwald, Andreas, additional

Published
2021
Full Text
View/download PDF

12. Treatment patterns and disease course of previously untreated Primary Central Nervous System Lymphoma: Feasibility of MTX‐based regimens in clinical routine

Author

Sieg, Noëlle, primary, Naendrup, Jan‐Hendrik, additional, Gödel, Philipp, additional, Balke‐Want, Hyatt, additional, Simon, Florian, additional, Deckert, Martina, additional, Gillessen, Sarah, additional, Kreissl, Stefanie, additional, Bröckelmann, Paul J., additional, Borchmann, Peter, additional, Tresckow, Bastian, additional, and Heger, Jan‐Michel, additional

Published
2021
Full Text
View/download PDF

13. How I treat advanced Hodgkin lymphoma — a global view

Author

Hokland, Peter, primary, Shah, Mansi, additional, David, Kevin, additional, Evens, Andrew, additional, Auer, Rebecca, additional, Ledieu, Rifca, additional, Kreissl, Stefanie, additional, Bröckelmann, Paul J., additional, Borchmann, Peter, additional, Korula, Anu, additional, Mathews, Vikram, additional, Owattanapanich, Weerapat, additional, and Trotman, Judith, additional

Published
2020
Full Text
View/download PDF

15. Patient and physician preferences for first‐line treatment of classical Hodgkin lymphoma in Germany, France and the United Kingdom

Author

Bröckelmann, Paul J., primary, McMullen, Suzanne, additional, Wilson, J Ben, additional, Mueller, Kerstin, additional, Goring, Sarah, additional, Stamatoullas, Aspasia, additional, Zagadailov, Erin, additional, Gautam, Ashish, additional, Huebner, Dirk, additional, Dalal, Mehul, additional, and Illidge, Tim, additional

Published
2018
Full Text
View/download PDF

16. Brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma who are Ineligible for autologous stem cell transplant: A Germany and United Kingdom retrospective study

Author

Bröckelmann, Paul J., primary, Zagadailov, Erin A., additional, Corman, Shelby L., additional, Chirikov, Viktor, additional, Johnson, Courtney, additional, Macahilig, Cynthia, additional, Seal, Brian, additional, Dalal, Mehul R., additional, and Illidge, Tim, additional

Published
2017
Full Text
View/download PDF

18. Clinical characteristics and outcomes of patients with Hodgkin lymphoma with central nervous system involvement: An international multicenter collaboration

Author

Cheah, Chan Y., primary, Bröckelmann, Paul J., additional, Chihara, Dai, additional, Moskowitz, Alison J., additional, Engert, Andreas, additional, Jerkeman, Mats, additional, El-Galaly, Tarec C., additional, Augustson, Bradley, additional, Vose, Julie, additional, Bartlett, Nancy L., additional, Villa, Diego, additional, Connors, Joseph M., additional, Feldman, Tatyana, additional, Pinnix, Chelsea C., additional, Milgrom, Sarah A., additional, Dabaja, Bouthaina, additional, Oki, Yasuhiro, additional, and Fanale, Michelle A., additional

Published
2016
Full Text
View/download PDF

19. Impact of centralized diagnostic review on quality of initial staging in Hodgkin lymphoma: experience of the German Hodgkin Study Group

Author

Bröckelmann, Paul J., primary, Goergen, Helen, additional, Fuchs, Michael, additional, Kriz, Jan, additional, Semrau, Robert, additional, Baues, Christian, additional, Kobe, Carsten, additional, Behringer, Karolin, additional, Eichenauer, Dennis A., additional, von Tresckow, Bastian, additional, Klimm, Beate, additional, Halbsguth, Teresa, additional, Wongso, Diana, additional, Plütschow, Annette, additional, Haverkamp, Heinz, additional, Dietlein, Markus, additional, Eich, Hans T., additional, Stein, Harald, additional, Diehl, Volker, additional, Borchmann, Peter, additional, and Engert, Andreas, additional

Published
2015
Full Text
View/download PDF

20. Human leukocyte antigen (HLA) class I expression on Hodgkin-Reed-Sternberg cells is an EBV-independent major determinant of microenvironment composition in classic Hodgkin lymphoma.

Author

Müller-Meinhard B, Seifert N, Grund J, Reinke S, Yalcin F, Kaul H, Borchmann S, von Tresckow B, Borchmann P, Plütschow A, Richter J, Engert A, Altenbuchinger M, Bröckelmann PJ, and Klapper W

Abstract

Hodgkin-Reed-Sternberg cells (HRSCs) in classic Hodgkin Lymphoma (HL) frequently lack expression of human leukocyte antigen class I (HLA-I), considered to hamper activation of cytotoxic T cells in the tumor microenvironment (TME). Here, we demonstrate HLA-I expression on HRSCs to be a strong determinant of TME composition whereas expression of HLA-II was associated with only minor differential gene expression in the TME. In HLA-I-positive HL the HRSC content and expression of CCL17/TARC in HRSCs are low, independent of the presence of Epstein-Barr virus in HRSCs. Additionally, HLA-I-positive HL shows a high content of CD8+ cytotoxic T cells. However, an increased expression of the inhibitory immune checkpoint LAG3 on CD8+ T cells in close proximity to HRSCs is observed. Suggesting interference with cytotoxic activity, we observed an absence of clonally expanded T cells in the TME. While HLA-I-positive HL is not associated with an unfavorable clinical course in our cohorts, they share features with the recently described H2 subtype of HL. Given the major differences in TME composition, immune checkpoint inhibitors may differ in their mechanism of action in HLA-I-positive compared to HLA-I-negative HL., Competing Interests: Dr von Tresckow is an advisor or consultant for Allogene, BMS/Celgene, Cerus, Incyte, IQVIA, Gilead Kite, Lilly, Miltenyi, Novartis, Noscendo, Pentixapharm, Roche, Amgen, Pfizer, Takeda, Merck Sharp & Dohme, and Gilead Kite; has received honoraria from AstraZeneca, BMS, Incyte, Lilly, Novartis, Roche Pharma AG, Takeda, and Merck Sharp & Dohme; reports research funding from Novartis (Inst), Merck Sharp & Dohme (Inst), and Takeda (Inst); and reports travel support from AbbVie, AstraZeneca, Gilead Kite, Lilly, Merck Sharp & Dohme, Pierre Fabre, Roche, Takeda, and Novartis all outside the submitted work. Dr P. Borchmann reports grants from BMS during the conduct of the study. Dr Engert reports grants and nonfinancial support from BMS during the conduct of the study, and personal fees from Takeda, BMS, and MSD outside the submitted work. Dr Bröckelmann is an advisor or consultant for BeiGene, BMS, MSD, Stemline, and Takeda, received honoraria from BeiGene, BMS, MSD, Stemline, and Takeda, received travel support from BeiGene, Celgene, and Takeda, and reports research funding from BeiGene (Inst), BMS (Inst), MSD (Inst) and Takeda (Inst). Dr Klapper reports grants from Roche, Amgen, Takeda, Incyte, and Regeneron paid to his institution outside the submitted work. The remaining authors declare no conflicts of interest., (© 2024 The Authors. HemaSphere published by John Wiley & Sons Ltd on behalf of European Hematology Association.)

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results